ES2187030T3 - Una nueva sal. - Google Patents
Una nueva sal.Info
- Publication number
- ES2187030T3 ES2187030T3 ES98925993T ES98925993T ES2187030T3 ES 2187030 T3 ES2187030 T3 ES 2187030T3 ES 98925993 T ES98925993 T ES 98925993T ES 98925993 T ES98925993 T ES 98925993T ES 2187030 T3 ES2187030 T3 ES 2187030T3
- Authority
- ES
- Spain
- Prior art keywords
- tartrate
- salt
- new salt
- dicyclobutylamino
- benzopyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a un nuevo hidrógeno-tartrato de (R)-3-N,N-diciclobutilamino-8-fluoro.3,4-dihidro-2H-1-benzopiran-5-carboxamido, particularmente a su tartrato-(2R,3R), y más particularmente al monohidrato de tartrato (R)-3-N,N-diciclobutilamino-8-fluoro-3,3-dihidro-2H-1-benzopiran-5-carbonamido. La invención también se refiere a un proceso para la fabricación de la sal de tartrato, a la utilización de la sal en la medicina, a la utilización de la sal del tartrato en la fabricación de formulaciones farmacéuticas y a un procedimiento para el tratamiento de las enfermedades del SNC mediante la administración de la sal del tartrato a un sujeto que necesite el tratamiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9702066A SE510305C2 (sv) | 1997-05-30 | 1997-05-30 | Nytt salt |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2187030T3 true ES2187030T3 (es) | 2003-05-16 |
Family
ID=20407187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98925993T Expired - Lifetime ES2187030T3 (es) | 1997-05-30 | 1998-05-15 | Una nueva sal. |
Country Status (34)
Country | Link |
---|---|
US (2) | US6858645B2 (es) |
EP (1) | EP0984952B1 (es) |
JP (1) | JP3554338B2 (es) |
KR (1) | KR20010013127A (es) |
CN (1) | CN1198814C (es) |
AR (1) | AR012751A1 (es) |
AT (1) | ATE228121T1 (es) |
AU (1) | AU729301B2 (es) |
BG (1) | BG64051B1 (es) |
BR (1) | BR9809519A (es) |
CA (1) | CA2291732C (es) |
DE (1) | DE69809547T2 (es) |
DK (1) | DK0984952T3 (es) |
EE (1) | EE03874B1 (es) |
ES (1) | ES2187030T3 (es) |
HK (1) | HK1025575A1 (es) |
HU (1) | HUP0001878A3 (es) |
ID (1) | ID23794A (es) |
IL (1) | IL133234A (es) |
IS (1) | IS1943B (es) |
MY (1) | MY117960A (es) |
NO (1) | NO995853L (es) |
NZ (1) | NZ501075A (es) |
PL (1) | PL337181A1 (es) |
PT (1) | PT984952E (es) |
RU (1) | RU2193560C2 (es) |
SE (1) | SE510305C2 (es) |
SK (1) | SK282755B6 (es) |
TR (1) | TR199902926T2 (es) |
TW (1) | TW510899B (es) |
UA (1) | UA53720C2 (es) |
WO (1) | WO1998054166A1 (es) |
YU (1) | YU62499A (es) |
ZA (1) | ZA984486B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102888D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
SE0102886D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
SE0301796D0 (sv) * | 2003-06-19 | 2003-06-19 | Astrazeneca Ab | New use II |
SE0301795D0 (sv) * | 2003-06-19 | 2003-06-19 | Astrazeneca Ab | New use I |
EP2022110B1 (en) * | 2006-05-11 | 2011-10-12 | Johnson Controls Saft Advanced Power Solutions LLC | Modular battery system |
JP5163931B2 (ja) * | 2007-03-08 | 2013-03-13 | 株式会社リコー | 定着装置及び画像形成装置 |
EP2065385A1 (en) * | 2007-11-28 | 2009-06-03 | Laboratorios SALVAT, S.A. | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
CN101747305B (zh) * | 2008-11-28 | 2014-06-18 | 中国医学科学院药物研究所 | 硝克柳胺化合物晶v型、其制法和其药物组合物与用途 |
LT2989095T (lt) * | 2013-04-26 | 2019-03-12 | Sanofi | 5-chlortiofen-2-karboksirūgšties [(s)-2-[metil-3-(2-okso-pirolidin-1-il)-benzensulfonilamino]-3-(4-metilpiperazin-1 -il)-3-oksopropil]amido tartrato druska |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5420151A (en) * | 1989-12-22 | 1995-05-30 | Aktiebolaget Astra | Chroman derivatives |
US5616610A (en) * | 1989-12-22 | 1997-04-01 | Astra Aktiebolag | (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans |
US5990114A (en) * | 1996-02-28 | 1999-11-23 | Recordati, S.A., Chemical And Pharmaceutical Company | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence |
IT1282705B1 (it) | 1996-02-28 | 1998-03-31 | Recordati Chem Pharm | Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria |
-
1997
- 1997-05-30 SE SE9702066A patent/SE510305C2/sv not_active IP Right Cessation
-
1998
- 1998-05-13 TW TW087107397A patent/TW510899B/zh active
- 1998-05-15 PL PL98337181A patent/PL337181A1/xx unknown
- 1998-05-15 CN CNB988056631A patent/CN1198814C/zh not_active Expired - Fee Related
- 1998-05-15 HU HU0001878A patent/HUP0001878A3/hu unknown
- 1998-05-15 AU AU77923/98A patent/AU729301B2/en not_active Ceased
- 1998-05-15 NZ NZ501075A patent/NZ501075A/en unknown
- 1998-05-15 EP EP98925993A patent/EP0984952B1/en not_active Expired - Lifetime
- 1998-05-15 YU YU62499A patent/YU62499A/sh unknown
- 1998-05-15 ID IDW991407A patent/ID23794A/id unknown
- 1998-05-15 US US09/077,718 patent/US6858645B2/en not_active Expired - Fee Related
- 1998-05-15 ES ES98925993T patent/ES2187030T3/es not_active Expired - Lifetime
- 1998-05-15 DK DK98925993T patent/DK0984952T3/da active
- 1998-05-15 CA CA002291732A patent/CA2291732C/en not_active Expired - Fee Related
- 1998-05-15 JP JP50056099A patent/JP3554338B2/ja not_active Expired - Fee Related
- 1998-05-15 WO PCT/SE1998/000907 patent/WO1998054166A1/en not_active Application Discontinuation
- 1998-05-15 UA UA99127241A patent/UA53720C2/uk unknown
- 1998-05-15 IL IL13323498A patent/IL133234A/en not_active IP Right Cessation
- 1998-05-15 PT PT98925993T patent/PT984952E/pt unknown
- 1998-05-15 TR TR1999/02926T patent/TR199902926T2/xx unknown
- 1998-05-15 SK SK1594-99A patent/SK282755B6/sk unknown
- 1998-05-15 BR BR9809519-6A patent/BR9809519A/pt not_active IP Right Cessation
- 1998-05-15 KR KR19997011107A patent/KR20010013127A/ko active IP Right Grant
- 1998-05-15 EE EEP199900549A patent/EE03874B1/xx not_active IP Right Cessation
- 1998-05-15 DE DE69809547T patent/DE69809547T2/de not_active Expired - Fee Related
- 1998-05-15 AT AT98925993T patent/ATE228121T1/de not_active IP Right Cessation
- 1998-05-15 RU RU99128026/04A patent/RU2193560C2/ru not_active IP Right Cessation
- 1998-05-26 AR ARP980102434A patent/AR012751A1/es unknown
- 1998-05-26 ZA ZA984486A patent/ZA984486B/xx unknown
- 1998-05-29 MY MYPI98002400A patent/MY117960A/en unknown
-
1999
- 1999-11-24 IS IS5270A patent/IS1943B/is unknown
- 1999-11-29 NO NO995853A patent/NO995853L/no not_active Application Discontinuation
- 1999-12-03 BG BG103949A patent/BG64051B1/bg unknown
-
2000
- 2000-08-08 HK HK00104934A patent/HK1025575A1/xx not_active IP Right Cessation
-
2004
- 2004-10-12 US US10/964,388 patent/US20050085532A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
DE60216830D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen | |
DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
BR9713186A (pt) | Inibidores de metaloprotease 1,3-diheterocìclicos | |
BR0009043A (pt) | Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença | |
TW200510375A (en) | New compounds | |
AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
HUP0203325A2 (hu) | Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DK0490772T3 (da) | 1,4-disubstituerede piperaziner, fremgangsmåde til fremstilling heraf og farmaceutiske midler, der indeholder dem | |
NO20030724L (no) | Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser | |
LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
AR047719A1 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri | |
ES2187030T3 (es) | Una nueva sal. | |
HUP0004282A2 (hu) | 2-Halogén-6-0-szubsztituált ketolidszármazékok | |
MX163574B (es) | Procedimiento para preparar una composicion farmaceutica para inhalacion conteniendo un gangliosido | |
HUP0203295A2 (hu) | Emphysema kezelése RAR-szelektív retinoid agonistákat tartalmazó gyógyszerkészítmények felhasználásával | |
AR066455A2 (es) | Uso de compuestos n-metil-n-[(1r)-1-fenil-2-(3r)-3-hidroxipirrolidin -1-il-=-etil]-2,2-difenilacetamida para producir un medicamento para el tratamiento de emfermedades intestinales no inflamatorias | |
DE69928806D1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
HUP0300863A2 (hu) | N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény | |
AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
MEP39708A (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
ES2140544T3 (es) | Utilizacion de efaroxan y de sus derivados para la fabricacion de medicamentos destinados al tratamiento de las enfermedades neurodegenerativas. | |
ATE201993T1 (de) | Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie |